Adjunctive selective estrogen receptor modulator increases neural activity in the hippocampus and inferior frontal gyrus during emotional face recognition in schizophrenia

Translational Psychiatry

Volumn 6, Issue , 2016, Pages

  Ji, E ^a,b   Weickert, C S ^a,b,c   Lenroot, R ^a,b,c   Kindler, J ^a,b,d   Skilleter, A J ^a,b,c   Vercammen, A ^a,b,c   White, C ^e   Gur, R E ^f   Weickert, T W ^a,b,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^c SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF BERN   (Switzerland)

^e PRINCE OF WALES HOSPITAL   (Australia)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; AMYGDALA; ANGER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ELECTROENCEPHALOGRAM; EMOTION; FACIAL RECOGNITION; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HIPPOCAMPUS; HUMAN; INFERIOR FRONTAL GYRUS; MALE; NERVE CELL; RANDOMIZED CONTROLLED TRIAL; REACTION TIME; SCHIZOPHRENIA; SOCIAL INTERACTION; BRAIN MAPPING; CROSSOVER PROCEDURE; DRUG EFFECTS; FACE; FRONTAL LOBE; IMAGE PROCESSING; NERVE CELL NETWORK; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; RECOGNITION;

ADULT; BRAIN MAPPING; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EMOTIONS; FACE; FEMALE; FRONTAL LOBE; HIPPOCAMPUS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; NERVE NET; RALOXIFENE HYDROCHLORIDE; RECOGNITION (PSYCHOLOGY); SCHIZOPHRENIA; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 84966292072     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2016.59     Document Type: Article

References (102)

1. Rosenheck R, Leslie D, Keefe R, McEvoy J, Swartz M, Perkins D et al. Barriers to employment for people with schizophrenia. Am J Psychiatry 2006; 163: 411-417.
2. Gur RE, Calkins ME, Gur RC, Horan WP, Nuechterlein KH, Seidman LJ et al. The Consortium on the Genetics of Schizophrenia: neurocognitive endophenotypes. Schizophr Bull 2007; 33: 49-68.
3. Weickert TW, Goldberg TE, Gold JM, Bigelow LB, Egan MF, Weinberger DR. Cognitive impairments in patients with schizophrenia displaying preserved and compromised intellect. Arch Gen Psychiatry 2000; 57: 907-913.
4. Kohler CG, Bilker W, Hagendoorn M, Gur RE, Gur RC. Emotion recognition deficit in schizophrenia: association with symptomatology and cognition. Biol Psychiatry 2000; 48: 127-136.
5. Schneider F, Gur RC, Koch K, Backes V, Amunts K, Shah NJ et al. Impairment in the specificity of emotion processing in schizophrenia. Am J Psychiatry 2006; 163: 442-447.
6. Levine SZ, Rabinowitz J, Ascher-Svanum H, Faries DE, Lawson AH. Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: evidence from the CATIE study. Schizophr Res 2011; 133: 42-46.
7. Burke KC, Burke JD Jr, Regier DA, Rae DS. Age at onset of selected mental disorders in five community populations. Arch Gen Psychiatry 1990; 47: 511-518.
8. Goldstein JM, Link BG. Gender and the expression of schizophrenia. J Psychiatr Res 1988; 22: 141-155.
9. Gur RE, Petty RG, Turetsky BI, Gur RC. Schizophrenia throughout life: sex differences in severity and profile of symptoms. Schizophr Res 1996; 21: 1-12.
10. Loranger AW. Sex difference in age at onset of schizophrenia. Arch Gen Psychiatry 1984; 41: 157-161.
11. Häfner H. Gender differences in schizophrenia. Psychoneuroendocrinology 2003; 28: 17-54.
12. Ochoa S, Usall J, Cobo J, Labad X, Kulkarni J. Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review. Schizophr Res Treatment 2012; 2012: 916198.
13. Hallonquist JD, Seeman MV, Lang M, Rector NA. Variation in symptom severity over the menstrual cycle of schizophrenics. Biol Psychiatry 1993; 33: 207-209.
14. Huber TJ, Rollnik J, Wilhelms J, von zur Muhlen A, Emrich HM, Schneider U. Estradiol levels in psychotic disorders. Psychoneuroendocrinology 2001; 26: 27-35.
15. Riecher-Rössler A, Häfner H, Maurer K, Stummbaum M, Schmidt R. Schizophrenic symptomatology varies with serum estradiol levels during menstrual cycle. Schizophr Res 1992; 6: 114-115.
16. Riecher-Rossler A, Hafner H, Stumbaum M, Maurer K, Schmidt R. Can estradiol modulate schizophrenic symptomatology? Schizophr Bull 1994; 20: 203-214.
17. Gogos A, Sbisa AM, Sun J, Gibbons A, Udawela M, Dean B. A role for estrogen in schizophrenia: clinical and preclinical findings. Int J Endocrinol 2015; 2015: 615356.
18. Riecher-Rossler A, Kulkarni J. Estrogens and gonadal function in schizophrenia and related psychoses. Curr Top Behav Neurosci 2011; 8: 155-171.
19. Seeman MV, Lang M. The role of estrogens in schizophrenia gender differences. Schizophr Bull 1990; 16: 185-194.
20. Bethea CL, Mirkes SJ, Su A, Michelson D. Effects of oral estrogen, raloxifene and arzoxifene on gene expression in serotonin neurons of macaques. Psychoneuroendocrinology 2002; 27: 431-445.
21. Biegon A, McEwen BS. Modulation by estradiol of serotonin receptors in brain. J Neurosci 1982; 2: 199-205.
22. Di Paolo T. Modulation of brain dopamine transmission by sex steroids. Rev Neurosci 1994; 5: 27-41.
23. Hafner H, Behrens S, De Vry J, Gattaz WF. An animal model for the effects of estradiol on dopamine-mediated behavior: implications for sex differences in schizophrenia. Psychiatry Res 1991; 38: 125-134.
24. Resnick SM, Maki PM. Effects of hormone replacement therapy on cognitive and brain aging. Ann N Y Acad Sci 2001; 949: 203-214.
25. Akhondzadeh S, Nejatisafa AA, Amini H, Mohammadi MR, Larijani B, Kashani L et al. Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 1007-1012.
26. Begemann MJ, Dekker CF, van Lunenburg M, Sommer IE. Estrogen augmentation in schizophrenia: a quantitative review of current evidence. Schizophr Res 2012; 141: 179-184.
27. Kulkarni J, de Castella A, Fitzgerald PB, Gurvich CT, Bailey M, Bartholomeusz C et al. Estrogen in severe mental illness: a potential new treatment approach. Arch Gen Psychiatry 2008; 65: 955-960.
28. Kulkarni J, de Castella A, Headey B, Marston N, Sinclair K, Lee S et al. Estrogens and men with schizophrenia: is there a case for adjunctive therapy?. Schizophr Res 2011; 125: 278-283.
29. Kulkarni J, de Castella A, Smith D, Taffe J, Keks N, Copolov D. A clinical trial of the effects of estrogen in acutely psychotic women. Schizophr Res 1996; 20: 247-252.
30. Kulkarni J, Gavrilidis E, Wang W, Worsley R, Fitzgerald PB, Gurvich C et al. Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age. Mol Psychiatry 2014.
31. Jacobs DM, Tang MX, Stern Y, Sano M, Marder K, Bell KL et al. Cognitive function in nondemented older women who took estrogen after menopause. Neurology 1998; 50: 368-373.
32. Tang MX, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996; 348: 429-432.
33. Zandi PP, Carlson MC, Plassman BL, Welsh-Bohmer KA, Mayer LS, Steffens DC et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA 2002; 288: 2123-2129.
34. Kian Tee M, Rogatsky I, Tzagarakis-Foster C, Cvoro A, An J, Christy RJ et al. Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors α and β. Mol Biol Cell 2004; 15: 1262-1272.
35. Lonard DM, Smith CL. Molecular perspectives on selective estrogen receptor modulators (SERMs): progress in understanding their tissue-specific agonist and antagonist actions. Steroids 2002; 67: 15-24.
36. MacGregor JI, Jordan VC. Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 1998; 50: 151-196.
37. Goekoop R, Barkhof F, Duschek EJJ, Netelenbos C, Knol DL, Scheltens P et al. Raloxifene treatment enhances brain activation during recognition of familiar items: a pharmacological fMRI study in healthy elderly males. Neuropsychopharmacology 2005; 31: 1508-1518.
38. Kulkarni J, Gurvich C, Lee SJ, Gilbert H, Gavrilidis E, de Castella A et al. Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinology 2010; 35: 1142-1147.
39. Usall J, Huerta-Ramos E, Iniesta R, Cobo J, Araya S, Roca M et al. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 2011; 72: 1552-1557.
40. Huerta-Ramos E, Iniesta R, Ochoa S, Cobo J, Miquel E, Roca M et al. Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. Eur Neuropsychopharmacol 2014; 24: 223-231.
41. Kindler J, Weickert CS, Skilleter AJ, Catts SV, Lenroot R, Weickert TW. Selective estrogen receptor modulation increases hippocampal activity during probabilistic association learning in schizophrenia. Neuropsychopharmacology 2015; 40: 2388-2397.
42. Weickert TW, Weinberg D, Lenroot R, Catts SV, Wells R, Vercammen A et al. Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia. Mol Psychiatry 2015; 20: 685-694.
43. Hooker C, Park S. Emotion processing and its relationship to social functioning in schizophrenia patients. Psychiatry Res 2002; 112: 41-50.
44. American Psychiatric Association, Task Force on D-I. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. American Psychiatric Association: Washington, DC, USA, 2000.
45. Edwards J, Pattison PE, Jackson HJ, Wales RJ. Facial affect and affective prosody recognition in first-episode schizophrenia. Schizophr Res 2001; 48: 235-253.
46. Gur RE, McGrath C, Chan RM, Schroeder L, Turner T, Turetsky BI et al. An fMRI study of facial emotion processing in patients with schizophrenia. Am J Psychiatry 2002; 159: 1992-1999.
47. Ji E, Weickert CS, Lenroot R, Catts SV, Vercammen A, White C et al. Endogenous testosterone levels are associated with neural activity in men with schizophrenia during facial emotion processing. Behav Brain Res 2015; 286: 338-346.
48. Phillips ML, Williams L, Senior C, Bullmore ET, Brammer MJ, Andrew C et al. A differential neural response to threatening and non-threatening negative facial expressions in paranoid and non-paranoid schizophrenics. Psychiatry Res 1999; 92: 11-31.
49. Adolphs R, Tranel D, Damasio H, Damasio A. Impaired recognition of emotion in facial expressions following bilateral damage to the human amygdala. Nature 1994; 372: 669-672.
50. Broks P, Young AW, Maratos EJ, Coffey PJ, Calder AJ, Isaac CL et al. Face processing impairments after encephalitis: amygdala damage and recognition of fear. Neuropsychologia 1998; 36: 59-70.
51. Calder AJ. Facial emotion recognition after bilateral amygdala damage: differentially severe impairment of fear. Cogn Neuropsychol 1996; 13: 699-745.
52. Hempel A, Hempel E, Schonknecht P, Stippich C, Schroder J. Impairment in basal limbic function in schizophrenia during affect recognition. Psychiatry Res 2003; 122: 115-124.
53. Li H, Chan RCK, McAlonan GM, Gong Q-y. Facial emotion processing in schizophrenia: a meta-analysis of functional neuroimaging data. Schizophr Bull 2010; 36: 1029-1039.
54. Takahashi H, Koeda M, Oda K, Matsuda T, Matsushima E, Matsuura M et al. An fMRI study of differential neural response to affective pictures in schizophrenia. Neuroimage 2004; 22: 1247-1254.
55. Williams LM, Das P, Harris AW, Liddell BB, Brammer MJ, Olivieri G et al. Dysregulation of arousal and amygdala-prefrontal systems in paranoid schizophrenia. Am J Psychiatry 2004; 161: 480-489.
56. Squire LR, Ojemann JG, Miezin FM, Petersen SE, Videen TO, Raichle ME. Activation of the hippocampus in normal humans: a functional anatomical study of memory. Proc Natl Acad Sci USA 1992; 89: 1837-1841.
57. Bellace M, Williams JM, Mohamed FB, Faro SH. An fMRI study of the activation of the hippocampus by emotional memory. Int J Neurosci 2013; 123: 121-127.
58. Buchanan TW. Retrieval of emotional memories. Psychol Bull 2007; 133: 761-779.
59. Phelps EA. Human emotion and memory: interactions of the amygdala and hippocampal complex. Curr Opin Neurobiol 2004; 14: 198-202.
60. Fusar-Poli P, Placentino A, Carletti F, Landi P, Allen P, Surguladze S et al. Functional atlas of emotional faces processing: a voxel-based meta-analysis of 105 functional magnetic resonance imaging studies. J Psychiatry Neurosci 2009; 34: 418-432.
61. Jeong B, Wible CG, Hashimoto R, Kubicki M. Functional and anatomical connectivity abnormalities in left inferior frontal gyrus in schizophrenia. Hum Brain Mapp 2009; 30: 4138-4151.
62. Lee S-K, Chun JW, Lee JS, Park H-J, Jung Y-C, Seok J-H et al. Abnormal neural processing during emotional salience attribution of affective asymmetry in patients with schizophrenia. PLoS One 2014; 9: e90792.
63. Kohler CG, Turner TH, Bilker WB, Brensinger CM, Siegel SJ, Kanes SJ et al. Facial emotion recognition in schizophrenia: intensity effects and error pattern. Am J Psychiatry 2003; 160: 1768-1774.
64. Mandal MK, Pandey R, Prasad AB. Facial expressions of emotions and schizophrenia: a review. Schizophr Bull 1998; 24: 399-412.
65. Kumari V, Fannon D, Peters ER, ffytche DH, Sumich AL, Premkumar P et al. Neural changes following cognitive behaviour therapy for psychosis: a longitudinal study. Brain 2011; 134: 2396-2407.
66. First M, Williams J, Spitzer R, Gibbon M. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Patient Edition, 1st revision edn. Biometrics Research Department, New York State Psychiatric Institute: New York, NY, USA, 2007.
67. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-276.
68. Wechsler D. Wechsler Test of Adult Reading. The Psychological Corporation: San Antonio, TX, USA, 2001.
69. Wechsler D. Wechsler Adult Intelligence Scale, Third Edition. Psychological Corporation: San Antonio, TX, USA, 1997.
70. Brett M, Anton J, Valabregue R, Poline J. Region of interest analysis using an SPM toolbox. Neuroimage 2002; 16: abstract S497.
71. Killgore WDS, Yurgelun-Todd DA. The right-hemisphere and valence hypotheses: could they both be right (and sometimes left)? Soc Cogn Affect Neurosci 2007; 2: 240-250.
72. Papanicolaou AC, Simos PG, Castillo EM, Breier JI, Katz JS, Wright AA. The hippocampus and memory of verbal and pictorial material. Learn Mem 2002; 9: 99-104.
73. Kelley WM, Miezin FM, McDermott KB, Buckner RL, Raichle ME, Cohen NJ et al. Hemispheric specialization in human dorsal frontal cortex and medial temporal lobe for verbal and nonverbal memory encoding. Neuron 1998; 20: 927-936.
74. Russell TA, Rubia K, Bullmore ET, Soni W, Suckling J, Brammer MJ et al. Exploring the social brain in schizophrenia: left prefrontal underactivation during mental state attribution. Am J Psychiatry 2000; 157: 2040-2042.
75. Peeters SCT, van Bronswijk S, van de Ven V, Gronenschild EHBM, Goebel R, van Os J et al. Cognitive correlates of frontoparietal network connectivity 'at rest' in individuals with differential risk for psychotic disorder. Eur Neuropsychopharmacol 2015; 25: 1922-1932.
76. Broca P. Remarques sur le siège de la faculté du langage articulé; suivies d'uneobservation d'aphémie (perte de la parole). Bull Soc Anat Paris 1861; 36: 330-356.
77. Suslow T, Lindner C, Dannlowski U, Walhofer K, Rodiger M, Maisch B et al. Automatic amygdala response to facial expression in schizophrenia: initial hyperresponsivity followed by hyporesponsivity. BMC Neurosci 2013; 14: 140.
78. Britton JC, Shin LM, Barrett LF, Rauch SL, Wright CI. Amygdala and fusiform gyrus temporal dynamics: responses to negative facial expressions. BMC Neurosci 2008; 9: 44.
79. Wright CI, Fischer H, Whalen PJ, McInerney SC, Shin LM, Rauch SL. Differential prefrontal cortex and amygdala habituation to repeatedly presented emotional stimuli. Neuroreport 2001; 12: 379-383.
80. Cyr M, Landry M, Di Paolo T. Modulation by estrogen-receptor directed drugs of 5-hydroxytryptamine-2 A receptors in rat brain. Neuropsychopharmacology 2000; 23: 69-78.
81. Landry M, Levesque D, Di Paolo T. Estrogenic properties of raloxifene, but not tamoxifen, on D2 and D3 dopamine receptors in the rat forebrain. Neuroendocrinology 2002; 76: 214-222.
82. Sánchez MG, Bourque M, Morissette M, Di Paolo T. Steroids-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther 2010; 16: e43-e71.
83. Kulla A, Manahan-Vaughan D. Depotentiation in the dentate gyrus of freely moving rats is modulated by D1/D5 dopamine receptors. Cereb Cortex 2000; 10: 614-620.
84. Rossato JI, Bevilaqua LRM, Izquierdo I, Medina JH, Cammarota M. Dopamine controls persistence of long-term memory storage. Science 2009; 325: 1017-1020.
85. Sajikumar S, Frey JU. Late-associativity, synaptic tagging, and the role of dopamine during LTP and LTD. Neurobiol Learn Mem 2004; 82: 12-25.
86. Badgaiyan RD, Fischman AJ, Alpert NM. Dopamine release during human emotional processing. Neuroimage 2009; 47: 2041-2045.
87. Suuronen T, Nuutinen T, Huuskonen J, Ojala J, Thornell A, Salminen A. Anti-inflammatory effect of selective estrogen receptor modulators (SERMs) in microglial cells. Inflamm Res 2005; 54: 194-203.
88. Fillman SG, Cloonan N, Catts VS, Miller LC, Wong J, McCrossin T et al. Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol Psychiatry 2013; 18: 206-214.
89. Fillman SG, Weickert TW, Lenroot RK, Catts SV, Bruggemann JM, Catts VS et al. Elevated peripheral cytokines characterize a subgroup of people with schizophrenia displaying poor verbal fluency and reduced Broca's area volume. Mol Psychiatry 2015; epub ahead of print 21 July 2015. doi: 10.1038/mp.2015.90.
90. Armagan G, Kanit L, Terek CM, Sozmen EY, Yalcin A. The levels of glutathione and nitrite-nitrate and the expression of Bcl-2 mRNA in ovariectomized rats treated by raloxifene against kainic acid. Int J Neurosci 2009; 119: 227-239.
91. Konyalioglu S, Durmaz G, Yalcin A. The potential antioxidant effect of raloxifene treatment: a study on heart, liver and brain cortex of ovariectomized female rats. Cell Biochem Funct 2007; 25: 259-266.
92. Emiliani FE, Sedlak TW, Sawa A. Oxidative stress and schizophrenia: recent breakthroughs from an old story. Curr Opin Psychiatry 2014; 27: 185-190.
93. Woolley CS, McEwen BS. Estradiol regulates hippocampal dendritic spine density via an N-methyl-D-aspartate receptor-dependent mechanism. J Neurosci 1994; 14: 7680-7687.
94. Ciriza I, Carrero P, Azcoitia I, Lundeen SG, Garcia-Segura LM. Selective estrogen receptor modulators protect hippocampal neurons from kainic acid excitotoxicity: differences with the effect of estradiol. J Neurobiol 2004; 61: 209-221.
95. Montague D, Weickert CS, Tomaskovic-Crook E, Rothmond DA, Kleinman JE, Rubinow DR. Oestrogen receptor alpha localisation in the prefrontal cortex of three mammalian species. J Neuroendocrinol 2008; 20: 893-903.
96. Perlman WR, Matsumoto M, Beltaifa S, Hyde TM, Saunders RC, Webster MJ et al. Expression of estrogen receptor alpha exon-deleted mRNA variants in the human and non-human primate frontal cortex. Neuroscience 2005; 134: 81-95.
97. Bookheimer SY, Strojwas MH, Cohen MS, Saunders AM, Pericak-Vance MA, Mazziotta JC et al. Patterns of brain activation in people at risk for Alzheimer's Disease. N Engl J Med 2000; 343: 450-456.
98. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 2001; 98: 6917-6922.
99. Karuza EA, Emberson LL, Aslin RN. Combining fMRI and behavioral measures to examine the process of human learning. Neurobiol Learn Mem 2014; 109: 193-206.
100. Turk-Browne NB, Scholl BJ, Chun MM, Johnson MK. Neural evidence of statistical learning: efficient detection of visual regularities without awareness. J Cogn Neurosci 2009; 21: 1934-1945.
101. Heinssen RK, Liberman RP, Kopelowicz A. Psychosocial skills training for schizophrenia: lessons from the laboratory. Schizophr Bull 2000; 26: 21-46.
102. Li ZJ, Guo ZH, Wang N, Xu ZY, Qu Y, Wang XQ et al. Cognitive-behavioural therapy for patients with schizophrenia: a multicentre randomized controlled trial in Beijing, China. Psychol Med 2015; 45: 1893-1905.